Company: PRGO
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001585364-25-000122
Chunk: 132

Company: PERRIGO Co plc
Filing Date: 2025-08-06
Form: 10-Q
Item: Part II, Item 1
Chunk 132
---
 Hospital & Specialty Business and the sale of branded products; partially offset by

•$29.6 million increase, or 3.6%, due primarily to growth of $16.1 million in the Pain & Sleep Aids category led by restored supply of the Solpadeine brand, as well as higher net sales of $9.7 million in the Upper Respiratory category driven by higher cough/cold incidence and improved supply, partially offset by lower net sales of $7.7 million in the VMS category;

•$6.0 million increase from favorable foreign currency translation.

CSCI net sales by product category were as follows:

SalesSix Months Ended(in millions, except percentages)June 28, 2025June 29, 2024$ Change% ChangeSkin Care$234.4 $242.4 $(8.0)(3.3)%Upper Respiratory128.9 119.8 9.1 7.6 %Healthy Lifestyle127.3 122.1 5.2 4.2 %Pain and Sleep-Aids117.1 101.7 15.4 15.2 %VMS76.2 84.5 (8.3)(9.8)%Women's Health73.5 68.9 4.6 6.6 %Oral Care47.7 51.7 (4.0)(7.7)%Digestive Health19.5 18.0 1.5 8.3 %Other CSCI32.8 60.1 (27.3)(45.4)%Total CSCI$857.4 $869.3 $(11.9)(1.4)%

Sales in each category were driven primarily by: 

•Skin Care: Net sales of $234.4 million decreased 3.3%, due primarily to soft seasonal consumption trends compared to the prior year, primarily in sun and blister care, leading to lower sales of ACO® and Iwostin®, 

48

Perrigo Company plc - Item 2CSCI

and the unfavorable impact of 1.9% from divested businesses and exited product lines. These factors were partially offset by share growth in Compeed® and Sebamed®, despite the soft seasonal trends;

•Upper Respiratory: Net sales of $128.9 million increased 7.6%, inclusive of a 0.9% favorable effect of